Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Comparative analysis of epigenomes offers new opportunities to understand cellular differentiation, mutation effects and disease processes. But the scale and heterogeneity of epigenetic data present numerous computational challenges.
Researchers are testing a slew of targeted therapeutic strategies in lung cancer. Signs are emerging that these therapies are gaining increasing traction in what has long been one of oncology's minefields. Malorye Allison investigates.
Genetic testing for rare heart conditions might someday expand to more common cardiac ailments. Already there are signs testing is dramatically changing how some conditions are treated and doctors' definition of who a patient is. Stephen Strauss reports.
A recent Australian legal decision means that, unless faculty members are bound by an assignment or intellectual property policy, they may own inventions resulting from their research.
One of the biggest gaps in our knowledge about epigenomes is how their interplay with cellular signaling influences development, adult cellular differentiation and disease.
Cleantech can offer biotech professionals the same mission, means of support and use of talents and skills they can have in drug discovery and development.
The US Food and Drug Administration (FDA) decision to approve a generic heparin derivative without clinical safety or efficacy data raises the possibility that clinical trials might not always be required for the approval of follow-on biologics.